Ex vivo human tissue & organsconfirmed

Revalia Bio

Yale-linked company running Human Data Trials on donated, non-transplantable human organs kept functional by perfusion.

Notable

Reports two top pharma customers and revenue since launch (company statements).

Dec 4, 2025
Government funding, ARPA-H CATALYST
ARPA-H CATALYST team led by Draper with Revalia Bio, Yale and LifeShare Network, building AI models on human organ, organ-chip and multimodal data. Revalia reports the award as up to $26.7M.
up to $26.7M
accessnewswire.com(opens in new tab)
Sep 4, 2025
Venture financing, Seed
Seed to launch Human Data Trials on perfused donor organs.
$14.5M
biospace.com(opens in new tab)

No related news yet.